A prognostic model based on necroptosis-related genes for prognosis and therapy in bladder cancer

[1]  Jun‐hang Luo,et al.  m6A-immune-related lncRNA prognostic signature for predicting immune landscape and prognosis of bladder cancer , 2022, Journal of Translational Medicine.

[2]  Wengang Zhang,et al.  Neutrophil-related genes predict prognosis and response to immune checkpoint inhibitors in bladder cancer , 2022, Frontiers in Pharmacology.

[3]  Yilin Yan,et al.  Pyroptosis-Related Patterns Predict Tumor Immune Landscape and Immunotherapy Response in Bladder Cancer , 2022, Frontiers in Molecular Biosciences.

[4]  Luyun He,et al.  circREEP3 Drives Colorectal Cancer Progression via Activation of FKBP10 Transcription and Restriction of Antitumor Immunity , 2022, Advanced science.

[5]  Yuchao Lu,et al.  Identification and Quantification of Necroptosis Landscape on Therapy and Prognosis in Kidney Renal Clear Cell Carcinoma , 2022, Frontiers in Genetics.

[6]  H. Qiu,et al.  Annexin A1 promotes the progression of bladder cancer via regulating EGFR signaling pathway , 2022, Cancer Cell International.

[7]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[8]  Yilin Yan,et al.  A Novel Ferroptosis-Related Prognostic Signature Reveals Macrophage Infiltration and EMT Status in Bladder Cancer , 2021, Frontiers in Cell and Developmental Biology.

[9]  Ping Huang,et al.  Comprehensive Analysis Identifies Potential Ferroptosis-Associated mRNA Therapeutic Targets in Ovarian Cancer , 2021, Frontiers in Medicine.

[10]  Ming-Rong Wang,et al.  FKBP10 promotes proliferation of glioma cells via activating AKT-CREB-PCNA axis , 2021, Journal of biomedical science.

[11]  S. Ugel,et al.  Monocytes in the Tumor Microenvironment. , 2021, Annual review of pathology.

[12]  Y. Piao,et al.  DOK7 Inhibits Cell Proliferation, Migration, and Invasion of Breast Cancer via the PI3K/PTEN/AKT Pathway , 2021, Journal of oncology.

[13]  Q. Ma,et al.  Emodin Induced Necroptosis and Inhibited Glycolysis in the Renal Cancer Cells by Enhancing ROS , 2020, Oxidative medicine and cellular longevity.

[14]  D. Aldinucci,et al.  Trabectedin overcomes doxorubicin-resistance, counteracts tumor-immunosuppressive reprogramming of monocytes and decreases xenograft growth in Hodgkin lymphoma. , 2020, Cancer letters.

[15]  Andrew Menzies,et al.  Extensive heterogeneity in somatic mutation and selection in the human bladder , 2020, Science.

[16]  H. Ueno,et al.  Shared and distinct roles of T peripheral helper and T follicular helper cells in human diseases , 2020, Cellular & Molecular Immunology.

[17]  J. Witjes,et al.  European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. , 2020, European urology.

[18]  T. Chan,et al.  Role of Microtubule-Associated Protein 1b in Urothelial Carcinoma: Overexpression Predicts Poor Prognosis , 2020, Cancers.

[19]  Xiao-chun Wei,et al.  Annexin A1 involved in the regulation of inflammation and cell signaling pathways , 2020, Chinese journal of traumatology = Zhonghua chuang shang za zhi.

[20]  Yongxiu Yang,et al.  SPOCD1 accelerates ovarian cancer progression and inhibits cell apoptosis via the PI3K/AKT pathway , 2020, OncoTargets and therapy.

[21]  X. Gou,et al.  Identification and analysis of long non-coding RNA related miRNA sponge regulatory network in bladder urothelial carcinoma , 2019, Cancer Cell International.

[22]  S. Sleijfer,et al.  The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies , 2019, Nature Genetics.

[23]  I. Melero,et al.  Dendritic cells in cancer immunology and immunotherapy , 2019, Nature Reviews Immunology.

[24]  D. Baker,et al.  Intratumoral activation of the necroptotic pathway components RIPK1 and RIPK3 potentiates antitumor immunity , 2019, Science Immunology.

[25]  H. Nishikawa,et al.  Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target? , 2019, Cancer science.

[26]  Chao Yang,et al.  The role of necroptosis in cancer biology and therapy , 2019, Molecular Cancer.

[27]  C. Brennan,et al.  Tumor mutational load predicts survival after immunotherapy across multiple cancer types , 2019, Nature Genetics.

[28]  F. López-Ríos,et al.  Implementing TMB measurement in clinical practice: considerations on assay requirements , 2019, ESMO Open.

[29]  M. Najafi,et al.  CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review , 2018, Journal of cellular physiology.

[30]  Junbo Hu,et al.  M2 Macrophage-Derived Exosomes Promote Cell Migration and Invasion in Colon Cancer. , 2018, Cancer research.

[31]  L. Dyrskjøt,et al.  Biology of nonmuscle-invasive bladder cancer: pathology, genomic implications, and immunology , 2018, Current opinion in urology.

[32]  J. Pollard,et al.  Targeting macrophages: therapeutic approaches in cancer , 2018, Nature Reviews Drug Discovery.

[33]  Thomas J. Crisman,et al.  A molecular cascade modulates MAP1B and confers resistance to mTOR inhibition in human glioblastoma , 2018, Neuro-oncology.

[34]  W. Liao,et al.  Gene expression profiles for a prognostic immunoscore in gastric cancer , 2018, The British journal of surgery.

[35]  Pei Zhang,et al.  Association of Mixed Lineage Kinase Domain-Like Protein Expression With Prognosis in Patients With Colon Cancer , 2017, Technology in cancer research & treatment.

[36]  Devin P. Sullivan,et al.  A subcellular map of the human proteome , 2017, Science.

[37]  Suoni Li,et al.  Repression of DOK7 mediated by DNMT3A promotes the proliferation and invasion of KYSE410 and TE-12 ESCC cells. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[38]  J. Witjes,et al.  MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER , 2016 .

[39]  J. Lunceford,et al.  Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. , 2017, The Lancet. Oncology.

[40]  Minoru Kanehisa,et al.  KEGG: new perspectives on genomes, pathways, diseases and drugs , 2016, Nucleic Acids Res..

[41]  J. Witjes,et al.  A five-gene expression signature to predict progression in T1G3 bladder cancer. , 2016, European journal of cancer.

[42]  R. Küppers,et al.  Human memory B cells , 2016, Leukemia.

[43]  Jedd D. Wolchok,et al.  PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations , 2016, Science Translational Medicine.

[44]  D. Green,et al.  RIPK1 and NF-κB signaling in dying cells determines cross-priming of CD8+ T cells , 2015, Science.

[45]  A. Thorburn,et al.  Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics , 2015, Cell Research.

[46]  Ash A. Alizadeh,et al.  Robust enumeration of cell subsets from tissue expression profiles , 2015, Nature Methods.

[47]  Man Zhang,et al.  Correlation of ANXA1 expression with drug resistance and relapse in bladder cancer. , 2014, International journal of clinical and experimental pathology.

[48]  W. Xu,et al.  Clinical significance of down-regulated cylindromatosis gene in chronic lymphocytic leukemia , 2014, Leukemia & lymphoma.

[49]  W. Curran,et al.  Pronecrotic mixed lineage kinase domain‐like protein expression is a prognostic biomarker in patients with early‐stage resected pancreatic adenocarcinoma , 2013, Cancer.

[50]  S. Amin,et al.  RIP1 potentiates BPDE-induced transformation in human bronchial epithelial cells through catalase-mediated suppression of excessive reactive oxygen species. , 2013, Carcinogenesis.

[51]  Peter Vandenabeele,et al.  Necroptosis: the release of damage-associated molecular patterns and its physiological relevance. , 2013, Immunity.

[52]  T. Spector,et al.  DNA methylation profiling in breast cancer discordant identical twins identifies DOK7 as novel epigenetic biomarker , 2012, Carcinogenesis.

[53]  P. Vandenabeele,et al.  Molecular mechanisms of necroptosis: an ordered cellular explosion , 2010, Nature Reviews Molecular Cell Biology.

[54]  S. Hubbard,et al.  The cytoplasmic adaptor protein Dok7 activates the receptor tyrosine kinase MuSK via dimerization. , 2010, Molecular cell.

[55]  Matthew D. Wilkerson,et al.  ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking , 2010, Bioinform..

[56]  Junying Yuan,et al.  Necroptosis as an alternative form of programmed cell death. , 2010, Current opinion in cell biology.

[57]  J. Grotta,et al.  Necroptosis, a novel form of caspase‐independent cell death, contributes to neuronal damage in a retinal ischemia‐reperfusion injury model , 2009, Journal of neuroscience research.

[58]  Alexei Degterev,et al.  Identification of RIP1 kinase as a specific cellular target of necrostatins. , 2008, Nature chemical biology.

[59]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[60]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[61]  N. Copeland,et al.  Comparative genetics and evolution of annexin A13 as the founder gene of vertebrate annexins. , 2002, Molecular biology and evolution.

[62]  Scott W. Lowe,et al.  Apoptosis A Link between Cancer Genetics and Chemotherapy , 2002, Cell.